CVS Health (CVS 1.92%) delivered solid quarterly results throughout 2019 and reported impressive revenue and earnings beats in the third quarter. But that financial success didn't translate to stock performance as much as investors would have liked. CVS Health shares finished last year up 13% but lagged well behind the S&P 500 index.
The healthcare giant announced its 2019 full-year and fourth-quarter results before the market opened on Wednesday. And yet again, CVS delivered a solid performance. Here are the three most important things to know about the company's Q4 update.
1. Better-than-expected revenue
CVS Health reported fourth-quarter revenue of $66.9 billion, up 22% year over year. This result topped the consensus Wall Street Q4 revenue estimate of $63.97 billion.
The company's acquisition of Aetna in late 2018 was again the key to CVS' revenue growth. CVS Health's healthcare benefits segment, which includes Aetna and the SilverScript Medicare Part D prescription drug program business, generated revenue of nearly $17.2 billion in Q4, up 175% year over year.
Pharmacy services, including the company's pharmacy benefits manager (PBM), CVS Caremark, posted revenue of nearly $37.1 billion in the fourth quarter. This reflected a 6.2% year-over-year increase, driven primarily by higher drug prices and an increase in pharmacy claims volume.
CVS Health's weakest unit in Q4 was its retail/long term care (LTC) segment. Revenue for the segment totaled $22.6 billion in Q4, up 2.5% year over year. While the retail/LTC segment benefited from increased prescription volume and higher drug prices, its growth was held back by nonstop reimbursement pressure and a higher generic dispensing rate.
2. An easy earnings beat
The average analysts' estimate called for CVS Health to report Q4 adjusted earnings per share (EPS) of $1.68. CVS Health easily beat that estimate, reporting adjusted EPS of $1.73 in the fourth quarter. This result reflected a sharp decline from the adjusted EPS of $2.14 reported in the prior-year period. However, the 2018 Q4 result was boosted by an adjustment of $1.98 related to goodwill impairment.
According to generally accepted accounting principles (GAAP), CVS Health reported net income of $1.74 billion, or $1.33 per share. This was a big improvement from the GAAP net loss in the prior-year period of $421 million, or $0.37 per share. That net loss, though, was caused by goodwill impairment.
3. Guidance not quite up to par
CVS Health CEO Larry Merlo stated, "As a result of the significant progress we made in 2019, and meeting or exceeding our expectations for the year, we raised our outlook for 2020." The company expects full-year 2020 GAAP operating income will be between $12.8 billion and $13 billion. The company projects that adjusted operating income in 2020 will be between $15.5 billion and $15.8 billion. Cash flow from operations is anticipated to be in the range of $10.5 billion to $11 billion.
The main numbers investors were interested in with CVS' guidance, though, related to the bottom line. CVS expects GAAP diluted EPS from continuing operations for full-year 2020 will be between $5.47 and $5.60, with adjusted EPS between $7.04 and $7.17. The midpoint of the company's adjusted EPS range reflects only a tiny year-over-year increase. It was also below the Wall Street consensus estimate for full-year adjusted EPS of $7.15.
It's going to be much harder for CVS Health to report solid revenue and earnings growth in 2020 because it won't benefit from prior-year comparisons that don't include revenue from Aetna. The key to the company's success will be winning customers' business through new products and services.
The biggest wild card for CVS Health this year, though, could be the U.S. presidential election. Healthcare stocks, including CVS, could be highly volatile as prominent presidential candidates push for single-payer healthcare and potentially attack PBMs.